Antigen Discovery

Executive Summary

Antigen Discovery Inc. (ADI) leverages its proprietary high-throughput proteome microarray technology to accelerate antigen discovery for vaccines, diagnostics, and therapeutics. By translating genomic sequences into comprehensive protein arrays, the company enables rapid identification of antibody targets across a wide range of infectious diseases. Serving research institutions, biopharma, and government agencies globally, ADI has established itself as a key enabler in the infectious disease and vaccine development landscape. Its platform addresses critical bottlenecks in antigen discovery, reducing timelines from months to weeks, and has been deployed in collaborations targeting emerging pathogens and pandemic preparedness. With a growing pipeline of projects and a focus on high-impact diseases, ADI is well-positioned to capture value in the expanding vaccines and diagnostics market.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a major pharmaceutical collaboration for vaccine antigen discovery65% success
• Q4 2026Launch of a new diagnostic antigen panel for a high-burden infectious disease40% success
• Q2 2026Close of a Series B or later-stage funding round to scale commercialization50% success